One of the prevailing hypotheses suggests schizophrenia as a neurodevelopmental disorder, involving dysfunction of dopaminergic and glutamatergic systems. Accumulating evidence suggests mitochondria as an additional pathological factor in schizophrenia. An attractive model to study processes related to neurodevelopment in schizophrenia is reprogramming of somatic cells into induced pluripotent stem cells (iPSCs) and differentiating them into different neuronal lineages. iPSCs from three schizophrenia patients and from two controls were reprogrammed from hair follicle keratinocytes, because of their accessibility and common ectodermal origin with neurons. iPSCs were differentiated into Pax6 þ /Nestin þ neural precursors and then further differentiated into b3-Tubulin þ /tyrosine hydroxylase þ /DAT þ dopaminergic neurons. In addition, iPSCs were differentiated through embryonic bodies into b3-Tubulin þ /Tbox brain1 þ glutamatergic neurons. Schizophrenia-derived dopaminergic cells showed severely impaired ability to differentiate, whereas glutamatergic cells were unable to maturate. Mitochondrial respiration and its sensitivity to dopamine-induced inhibition were impaired in schizophrenia-derived keratinocytes and iPSCs. Moreover, we observed dissipation of mitochondrial membrane potential (Dc m ) and perturbations in mitochondrial network structure and connectivity in dopaminergic along the differentiation process and in glutamatergic cells. Our data unravel perturbations in neural differentiation and mitochondrial function, which may be interconnected, and of relevance to dysfunctional neurodevelopmental processes in schizophrenia.
INTRODUCTION
One of the prevailing hypotheses suggests schizophrenia as a neurodevelopmental disorder, based on clinical, epidemiological, brain-imaging and genetic studies. 1, 2 It is increasingly defined as a disorder of neural connectivity with abnormalities in synaptic pruning and regional synaptic deficit. 3 Changes in multiple neural systems have been suggested to underlie the pathophysiology of schizophrenia, specifically that of dopaminergic and glutamatergic systems. 4 Elevated dopamine activity in mesolimbic pathways and decreased activity in the prefrontal cortex as well as glutamatergic hypoactivity are observed in schizophrenia. It is suggested that abnormal hippocampal or frontal glutamatergic circuits result in dopaminergic hyperactivity in the nucleus accumbens and hypoactivity in the frontal cortex. 5 In addition, striatal and prefrontal cortical dopaminergic inputs regulate glutamatergic pathways, [6] [7] [8] [9] suggesting a dopaminergic glutamatergic reciprocal regulatory mechanism.
Mitochondria are one of the important factors in modulating neuronal activity and are essential for morphogenesis and plasticity of spines and synapses. 10 Accumulating genetic and molecular evidence implicates mitochondria in the pathophysiology of schizophrenia. [11] [12] [13] Our studies have shown abnormalities in mitochondrial respiration, in complex I (CoI), a major control component of the oxidative phosphorylation system, and in mitochondrial network dynamics in patients with schizophrenia.
14 Mitochondrial network dynamics alters in response to cell metabolic demand, is a crucial factor in the cross-talk between these organelles and the cell and is essential for embryonic development and synapse formation. 15 Interestingly, dopamine and glutamate have been shown to modulate mitochondrial function, [16] [17] [18] and in schizophrenia, a pathological interaction between dopamine and CoI has been reported. [19] [20] [21] [22] A major limitation in the study of schizophrenia is the inaccessibility of the brain and the lack of adequate experimental models. Induced pluripotent stem cells (iPSCs) can recapitulate in vitro aspects of patients' neuronal development and thus may aid to unravel early pathological processes in the disease. Recent studies in schizophrenia patients differentiated stem cells and iPSCs into neural cells. [23] [24] [25] [26] Brennand et al. 23, 27 and Brennand and Gage 24 showed impaired glutamatergic signaling in schizophrenia, including reduced neuronal connectivity, a decrease in neurite number and in PSD-95/MAP2AB ratio levels, as well as alterations in gene expression, substantiating the major pharmacological and genetic hypotheses of this disease. Moreover, they identified several pathways not previously implicated in schizophrenia, such as NOTCH signaling, SLIT/ROBO axon guidance, EFNA-mediated axon growth, cell adhesion and transcriptional silencing. 23, 24, 27 Other studies showed that early differentiating neurons expressed 26 In addition, altered oxygen consumption and increased ROS production were reported. 28, 29 Here, we report impaired differentiation into dopaminergic and glutamatergic neural lineages associated with mitochondrial dysfunction, in hair follicle keratinocyte (HFK)-derived iPSCs of three schizophrenia patients. HFKs were reprogrammed with the rationale that they originate from the same ectodermal layer as neurons and provide a painless non-invasive cell-acquiring method.
MATERIALS AND METHODS Subjects
Three patients suffering from paranoid schizophrenia in a stable clinical state under clozapine treatment with a family history of schizophrenia (Supplementary Figure 1G) were recruited to this study. Patients were diagnosed according to consensus by two senior psychiatrists based on the Diagnostic and Statistical Manual of Mental Disorders, fourth edition, text revision (DSM-IV-TR) and the severity of symptoms was assessed before hair follicle collection by the Positive and Negative Syndrome Scale (PANSS) and Clinical Global Impression (CGI) 30 rating scales (PANSS 480, CGI 44; Supplementary Table 1 ). The three patients and two healthy controls were recruited to this study, following approval by the Ethical Committee of Rambam Health Care Campus. Hair follicles were collected two times from patient 1 (1a and 1b) at a 1-year interval.
HFK culture and reprogramming into iPSCs HFK culturing and reprogramming was performed as described previously [31] [32] [33] (Supplementary Methods). iPSC pluripotency was assessed by TRA-1-60 and TRA-1-81 (Ab-1:100) immunofluorescence. Quantitative realtime polymerase chain reaction was performed in duplicates 31 using glyceraldehyde 3-phosphate dehydrogenase (unaffected by disease) for normalization. Karyotypes were analyzed in clones taken for differentiation. PluriTest analysis, a bioinformatic assay, which eliminates the need of animal use for teratoma assay, was employed and raw data processed as described previously. 34, 35 Embryonic bodies (EBs) were produced as described previously 26, 31, 36 and characterized by staining for Troponin-T (Ab-1:100) and by quantitative real-time polymerase chain reaction for expression levels of a-fetoprotein-1, CD31 and cytokeratin-14, endoderm, mesoderm and ectoderm markers, respectively. iPSC differentiation into dopaminergic and glutamatergic neurons Dopaminergic differentiation was performed according to the previously described dual SMAD inhibition protocol 31, 37 (Supplementary Methods). Differentiation into neural precursor cells (DA-NPs) was assessed by quantitative real-time polymerase chain reaction and by immunostaining of PAX6 (Ab-1:500) and Nestin (Ab-1:500). Differentiation into dopaminergic cells (DA-NCs) was assessed by quantitative real-time polymerase chain reaction and by immunostaining of b3-Tubulin (Ab-1:250), tyrosine hydroxylase (TH) (Ab-1:250) and dopamine membrane transporter (Ab-1:500).
Glutamatergic differentiation was performed as described previously 26, 36 without the addition of retinoic acid and Wnt3A, as both signaling molecules have been implicated in schizophrenia (Supplementary Methods). Differentiation into glutamatergic cells (Glu-NC) was assessed by immunostaining with b3-Tubulin (Ab-1:250) and Tbox brain1 (Tbr1) (Ab-1:100). Synaptic contact was assessed by immunostaining for postand presynaptic markers PSD-95 (Ab-1:500) and synapsin-1(Ab-1:1000) and their colocalization. Antibodies were purchased from Chemicon Millipore (Billerica, MA USA). Primer sequences are shown in Supplementary Table 2 .
A scheme of the dopaminergic and glutamatergic differentiation protocols is depicted in Supplementary Figure 2 .
To address possible variability in iPSC lines obtained after cell reprogramming, in differentiation efficiency 23 and in disease-independent variations, as well as to verify the reproducibility of the results, we repeated at a year interval the entire process of hair follicle plucking, keratinocytes reprogramming into iPSC and their differentiation into dopaminergic and glutamatergic neurons for patient 1 (1a and 1b) (Supplementary Figure 3) . In addition, for all five subjects the experiment was repeated three times using one clone for each subject at different passages (9-30).
Images were captured by an inverted microscope (Nikon 135; Zeiss, Jena, Germany) connected through a video camera to a Pentium MMX-PC. Low-density seeded cells were analyzed for their cell area, neurite outgrowth (number per cell and length) using the NIS-Elements AR 3.0 imaging software (Melville, NY, USA) after applying a manual grid. Immunofluorescence-integrated density was analyzed by the ImagePro (Miami, FL, USA) and Image-J software (NIH, Bethesda, MD, USA). All analyses were carried out in 8-10 fields obtained from the three experiments and averaged for each subject.
High-pressure liquid chromatography analyses
The concentration of monoamines and amino acids and their metabolites were assessed by high-pressure liquid chromatography (HPLC) with an electrochemical detector and fluorescence detector, respectively. 38, 39 Glutamate and glutamine levels were normalized to methionine levels, as methionine levels in the media remained constant during 24 h of culturing.
Mitochondrial respiration
Oxygen consumption was measured polarographically with a thermostatically controlled Clark oxygen electrode (Strathkelvin 782 Oxygen System, North Lanarkshire, Scotland). 20, 40 CoI-driven respiration in intact cells was determined in the absence and presence of dopamine (10 À 4 M) for up to 30 min. Since at least 2.5 Â 10 5 cells are required for a single measurement, respiration was performed only in keratinocytes and iPSCs.
Imaging mitochondrial membrane potential and network dynamics
Mitochondrial membrane potential (Dc m ) was assessed with 5,5 0 ,6,6 0 -tetrachloro-1,1 0 ,3,3 0 -tetraethylbenzimidazolocarbocyanine iodide (JC-1), which accumulates in the mitochondria depending on Dc m .
14 JC-1 color alters reversibly from green (J-monomer) to red (J-aggregates) with increasing Dc m . Images were acquired using Zeiss LSM510 Meta laser scanning confocal system (Carl Zeiss MicroImaging, Zeiss) with Â 63/1.4 oil objective following Â 4 digital zoom. Dc m was assessed as red to green ratio.
Mitochondria distribution was analyzed in projection images of all cell's z sections using the GIMP version 2.2.17 software (http://the-gimp. brothersoft.com/the-gimp2.2.17) as described previously. 14 The coefficient of variance between nine identical grid squares of each image, which was used to compare images for uniformity of red color distribution in cells, was calculated.
Mitochondria network connectivity was assessed by applying a focused laser beam (6A) to dissipate Dc m in preselected region of interest of 20 Â 20 pixels as described previously. 14 The extent of Dc m dissipation (red/green) after the laser beam application, inside a circle of a 60 pixels diameter around the region of interest, was used as a measure for network connectivity. Data analysis was performed using the LSM510 software version 4.2 (Zeiss).
Data analysis
For each subject, the data obtained from each experiment were averaged and considered as one data point. The data points obtained from all three experiments were averaged separately for each subject. The latter averages were analyzed for the significance of the differences between patients and controls. Data followed a normal distribution in the Kolmogorov-Smirnov test. Thus, parametric tests were used. Student's t-test was used to compare patients and control groups. SPSS 17.0 software (SPSS Inc., Chicago, IL, USA) was used.
RESULTS

Keratinocytes' culturing and reprogramming
There was no observable difference between patients and controls in keratinocytes' culturing and reprogramming processes (Supplementary Figure 1A) . iPSCs from patients and controls showed similar mRNA expression of pluripotency genes, Oct3/4, Sox2, Klf4, Nanog and Dnmt3b, to that of human embryonic stem cells. 41 The expression of Oct3/4 and Sox2 was gradually diminished during differentiation, both in patients and in controls (Supplementary Figures 1B and C) . All iPSC lines displayed high iPSC, neural differentiation and mitochondrial dysfunction in schizophrenia O Robicsek et al pluripotency scores within the empirically set boundaries of the PluriTest assay, similar to hES and to other fibroblast-derived iPSCs 34, 35, 42 (Supplementary Figure 1E) . Keratinocyte-derived iPSCs showed efficient neuroectodermal differentiation propensities, similar to our previous reports. 31, 43 Control and patient iPSCs were equally able to differentiate into the three germ layers, as illustrated by the formation of EBs and the expression of a-fetoprotein-1, CD31 and cytokeratin-14 ( Supplementary  Figures 1A and D) . Karyotype analysis of clones, at passages taken for differentiation, showed no abnormalities (Supplementary Figure 1F) . Differentiation into dopaminergic neurons At day 12 of differentiation, neural precursors (DA-NPs) were observed ( Figure 1a ). DA-NPs of patients exhibited morphological differences as compared with controls, expressed by a larger cell area (Po0.01), yet similar number and length of extensions (Figure 1c ). PAX6 and Nestin (early and advanced neuronal precursor markers, respectively) 41 were abnormally expressed in patient cells (Figure 1d ). PAX6 showed significantly higher immunostaining (Po0.03), while reduced mRNA expression in all three patient-derived DA-NPs. Nestin immunostaining (Po0.016) and mRNA levels, however, were both lower in patients as compared with controls, suggesting a delay in differentiation ( Figure 1e and Supplementary Figure 4A) .
At day 21, typical neurons (DA-NCs) were observed in controls, but less so in patients (Figure 1b) . Cells' neurite number and length were significantly greater (Po0.013 and Po0.011, respectively) in controls than in patients, with no difference in cell area (Figure 1c ). Immunostaining showed b3-Tubulin
In patients, however, only very few b3-Tubulin þ /TH þ cells were observed (Po0.0081, Po0.031, respectively), none expressing DAT (Figures 1f-h) . Similarly, mRNA expression levels of these genes were significantly lower in patients (Supplementary Figure 4B) . These differences were associated with a reduction in the release of dopamine (Po0.001), with no detection of its metabolite homovanillic acid, in patients as compared with controls. No such difference was observed for serotonin and its metabolite 5-hydroxyindoleacetic acid between patients and controls ( Figure 1i ). As expected, at 12 days of differentiation, HPLC analysis did not detect any of the monoamines in both control-and patient-derived cultures. None of these monoamines or metabolites was detected in the supplemented medium.
Differentiation into glutamatergic neurons
In parallel, we differentiated all subjects' iPSCs, through EBs, into glutamatergic neurons (Glu-NC). Unlike dopaminergic neurons, no significant difference was observed between controls and patients in cell area and in the number and length of neurites. EBs of both controls and patients differentiated into b3-Tubulin þ neurons, albeit to a lower extent in patients (Po0.0042). Only control cells expressed the glutamatergic maturation marker Tbr1 (Figures 2a  and b) . In addition, patients' cells showed decreased immunostaining of synapsin1 and PSD-95 (Po0.0095, Po0.0087, respectively) and their colocalization, indicating synaptic contacts, was significantly lower in patients (Po0.0066) (Figures 2c and d) .
HPLC amino-acid analysis showed reduced glutamate consumption, expressed by its higher levels, in the culture medium of patients' cells as compared with control (Po0.00089). Concomitantly, lower levels of released glutamine were observed in patients (Po0.0031) (Figure 2e ). The supplemented medium contained glutamate but not glutamine (Supplementary Table 3 ). 
Mitochondrial function
Mitochondrial basal respiration was impaired in patient-derived keratinocytes (Po0.047) but not in their iPSCs. However, inhibition of CoI-driven respiration by dopamine was twofold higher in patients' keratinocytes and iPSCs as compared with their respective control cells (Po0.001) ( Table 1) . Dc m was dissipated (Figure 3b ). mRNA expression of three genes encoding three subunits of CoI (NDUFV1, NDUFV2 and NDUFS1) and of one encoding OPA1, a major regulator of mitochondrial fusion, showed significant alteration in patients' iPSCs, DA-NPs and DA-NCs (Supplementary Figure 5) . Thus, in iPSC of patients all four genes were upregulated (Po0.04, Po0.03, Po0.03, Po0.04, respectively), in DA-NPs no significant change was observed, whereas in DA-NCs all genes except for NDUFS1 were significantly downregulated (Po0.001, Po0.001, Po0.12, Po0.05, respectively). 
DISCUSSION
The prevailing hypothesis of schizophrenia implicates abnormalities in both dopaminergic and glutamatergic transmission as a part of a more comprehensive paradigm that includes genetic and environmental risk factors that interact with each other to produce the variance in clinical symptoms of schizophrenia.
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The main finding of our study is the pervasive mitochondrial dysfunction in schizophrenia-derived cells associated with their impaired ability to differentiate into dopaminergic and into mature glutamatergic neurons. Our study further demonstrates a different degree of impairment between dopaminergic and glutamatergic cell lineages in schizophrenia. Thus, patients' glutamatergic cells differentiate into immature b3-Tubulin þ / Tbr1 À neurons with a higher efficiency than patients' dopaminergic cells, in which the differentiation was already impaired at the neural precursor stage. Only few dopaminergic cells were b3-Tubulin þ /TH þ in patients. None of them expressed DAT, a specific marker of mature dopaminergic neurons, unlike TH, which is also expressed by noradrenergic and most of other neurons in the young brain. 45, 46 Finally, morphological abnormalities were observed in patients' dopaminergic but not in glutamatergic cells. It is tempting to speculate that the severe impairment in dopaminergic cells is in line with clinical data showing the requirement of a dopaminergic component in clinically effective schizophrenia drugs. 47 Schizophrenia is currently conceptualized as a disorder of connectivity between components of large-scale brain networks. Different neurophysiological, imaging, neuropathological and molecular biological methods have revealed disrupted connectivity in schizophrenia patient with a consecutive reduction in synaptic and cellular plasticity, implicating also alterations in glutamatergic system as potential candidates. 48 In accordance with the latter, patient-derived glutamatergic cells displayed significantly less staining of synapsin1 and PSD-95 and reduced ability to form synaptic contacts.
The difference between control and patients was already expressed at the DA-NPs, as both PAX6 and Nestin showed abnormal levels and dissimilar intracellular distribution pattern in patients. PAX6 staining is typically observed in the nucleus in control cells, while in our patients' cells, PAX6 appears to be located also in the cytosol. Given that PAX6 encodes for five proteins, three of which have DNA-binding domain and are distributed into the nucleus, while two are devoid of this domain and are located both in the cytosol and in the nucleus, 49 our results suggest a higher expression of the cytosolic isoforms in patients. In addition, it was shown that PAX6 is subjected to direct autoregulation, 50, 51 which may contribute to the reduction in PAX6 mRNA expression observed in patients' DA-NP. Thus, the discrepancy between PAX6 mRNA expression levels and protein immunostaining in patients may be explained by a different pattern of alternative splicing of the PAX6 transcript in patients and/or a different timing between PAX6 gene silencing and its protein turnover. Nestin is typically expressed in the cytoplasm, yet in patients' DA-NP Nestin appeared to be located preferably in the nucleus. Interestingly, it was reported that in several cell line derived from neurogenic tumors, Nestin was present primarily in the nuclei of cells containing diffused Nestin signal in the cytoplasm. 52 In addition, in stem cell derived from ALS patients' neuronal differentiation medium induced a change in the pattern of Nestin staining from nuclear to cytoplasmatic, suggesting that at a lower differentiation stage Nestin staining is more nuclear. 53 Further studies are warranted to characterize PAX6 and Nestin expression in the schizophrenia DA-NP.
To further substantiate the differences in differentiation efficiency between patients and controls, we studied the release and metabolism of dopamine and glutamate, one of the fundamental functions of neurons. A significant reduction in dopamine turnover rate was observed in patient-derived cells. In glutamatergic cultures, there was no formation of glutamine and glutamate consumption was reduced, implying disrupted neural glutamate delivery via the glutamate-glutamine cycle, previously implicated in schizophrenia. 54 Notably, impaired turnover of dopamine and glutamate can also be indicative of an abnormal active reuptake mechanism, as the neurotransmitters are metabolized intracellularly in cultures. 55 A recent comprehensive study 23 also showed impairment in glutamatergic cells in schizophrenia. The thorough gene expression study identified alterations in many genes including those of the glutamate, WNT and cAMP signaling pathways, previously implicated in schizophrenia. In addition, they reported a tendency towards diminished neuronal connectivity, significant decrease in neurite number and in PSD-95/MAP2AB ratio levels. Yet unlike our data, they did not observe differences in b3-Tubulin, PSD-95 and synapsin levels. This discrepancy could stem from the differences in patients' sample. Our sample included homogenous DSM-IVTR-diagnosed paranoid-type severe schizophrenia patients with a family history of schizophrenia, treated with clozapine, while in the previous study, a heterogeneous sample, including several different subtypes of schizophrenia, was selected. In addition, we reprogrammed a different cell type, keratinocytes that originate from the same embryonic layer as neurons. In the previous study, normal spontaneous neural activity as measured by electrophysiology and calcium transient imaging was reported in patients. However, by analyzing alternative parameters of neuronal activity, monoamines and amino-acid release, as well as mitochondrial function, we showed impairments in schizophreniaderived dopaminergic and glutamatergic cells.
Mitochondrial dysfunction has been observed in various neuropsychiatric disorders including Alzheimer's, Parkinson's and Huntington's diseases, amyotrophic lateral sclerosis, schizophrenia and bipolar disorder. In these disorders, a wide spectrum of disease-specific mitochondrial abnormalities were observed ranging from genetic variations through network dynamics, trafficking and turnover of mitochondria to oxidative phosphorylation system defects. 12, 56 In our study, mitochondrial functional impairments as well as abnormal expression of three subunits of CoI, which were previously implicated in schizophrenia, were observed in patient-derived cells. Whether this dysfunction also affects differentiation is still an open question; nonetheless, it was reported that the mitochondria are important for neuronal survival, plasticity and differentiation. 57, 58 A recent study in a single schizophrenia fibroblast-derived iPSCs reported altered oxygen consumption in differentiated neural cell. 28 We show a dissipation of Dc m , indicative of the oxidative phosphorylation system activity, as well as uneven mitochondria cellular distribution, a feature of mitochondrial network morphology, in patient-derived iPSCs and along their differentiation stages into dopaminergic cells, as well as into glutamatergic neurons. In addition, impaired mitochondrial network connectivity was iPSC, neural differentiation and mitochondrial dysfunction in schizophrenia O Robicsek et al observed in patient-derived dopaminergic neurons, by both reduced spreading of Dc m dissipation and by the significant reduction in OPA1 mRNA levels. Unlike the dopaminergic neurons, glutamatergic neurons did show impaired mitochondrial network connectivity. Furthermore, mitochondrial respiration was reduced in keratinocytes but not in schizophrenia-derived iPSCs. However, dopamine pathological inhibition of CoI-driven respiration, previously observed in schizophrenia, [20] [21] [22] 40 was similar in both cell type. This inhibitory effect of dopamine, as well as Dc m dissipation and uneven mitochondrial cell distribution, was unaffected by reprogramming or differentiation stage, and therefore could represent an intrinsic feature of schizophrenia cells. Interestingly, in patients the expression of CoI subunits and of OPA1 was increased following reprogramming, while it decreased at the end of dopaminergic differentiation. The cause for this kinetic is still unclear. However, cell-and brain areadependent differences in gene expression were previously reported in schizophrenia. For example, CoI subunits showed an increase in blood cells, a decrease in prefrontal specimen, with no change in the cerebellum specimen, in schizophrenia. 59 Given neurons' strong dependence on energy production, it is conceivable that unlike somatic cells, neurons will be more afflicted by minor deviations from normal mitochondria functioning.
Our data demonstrate differences in the extent of impairment between patient-derived dopaminergic and glutamatergic cells. One may argue that these differences may not reflect intrinsic cellular mechanisms, but rather methodological variation. Indeed, we used different protocols of differentiation, one commencing from iPSCs and the other from EBs. However, in control cells, differentiation efficiency, as expressed by b3-Tubulin staining, was similar challenging the protocol-related interference. Still the possibility of ameliorating/deteriorating media factors cannot be ignored.
We studied mixed, yet enriched dopaminergic and glutamatergic neuronal populations, which may influence the results. Immunostaining and HPLC data, however, confirm specific dopaminergic and glutamatergic cell abnormalities in patients. We have shown impairments at three time points for dopaminergic differentiation (iPSCs, DA-NPs and DA-NCs) and at two time points for glutamatergic differentiation (iPSCs and Glu-NCs) in patients. These impairments could represent irreversible developmental deficits; however, the possibility of a delayed differentiation cannot be ruled out. Further long-term studies with multiple time point assessments are needed to address this important issue.
High glutamate levels (B55 mM) were detected by HPLC analysis of amino-acid concentrations in our medium, previously recommended for glutamatergic and dopaminergic differentiation protocols. 23, 26, 36, 37, 60 It is well known that glutamate can be toxic for neurons. However, in the synapse glutamate concentration can rise up to 1 mM, but is rapidly decreased mainly by extraneuronal uptake. 61, 62 In our cultures, which are mixed neuronal cultures, other cells that consume glutamate may protect the neurons. Interestingly, several reports indicate that at early stages of neuronal development higher glutamate concentrations (50-60 mM) are required and even promote their survival and proliferation. 63, 64 In our study, despite the high glutamate levels, control cells differentiated and expressed specific neuronal maturation markers. However, it is still possible that patients' cells are more sensitive to glutamate and therefore did not differentiate properly. This interesting point warrants further investigation. Our data were collected from a specific subtype of schizophrenia. We repeated the experiment three times using different passages for each of the five subjects and two different clones for one patient in an attempt to overcome disease-independent variations. However, an increased sample size and additional subtypes of the disorder are warranted to substantiate the relevance of our findings to schizophrenia.
Our findings in dopaminergic cells may appear counterintuitive with the accepted midbrain hyperdopaminergic hypothesis of schizophrenia. However, a hypodopaminergic state has been shown in the prefrontal cortex of schizophrenia patients. Midbrain dopamine is subjected to compensatory mechanisms, including those from the prefrontal cortex. Thus, the midbrain hyperdopaminergic state can be a compensatory response to the hypofrontal state. In this regard, our cellular model lacks the complexity of the brain and it is not expected to reflect brain deficits accurately in schizophrenia. Still our model can be of relevance to certain aspects of the complex pathological processes involved in this disease.
Finally, this study highlights the advantage of iPSC cellular model as a platform to identify molecular and cellular mechanisms involved in developmental aberrations in schizophrenia.
